Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Cash from Financing Activities (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of Cash from Financing Activities data on record, last reported at $26.0 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 95.32% year-over-year to $26.0 million; the TTM value through Dec 2025 reached $40.6 million, down 96.0%, while the annual FY2025 figure was $40.6 million, 96.0% down from the prior year.
  • Cash from Financing Activities reached $26.0 million in Q4 2025 per CRNX's latest filing, up from $3.1 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $556.2 million in Q4 2024 and bottomed at $57000.0 in Q1 2021.
  • Average Cash from Financing Activities over 5 years is $91.1 million, with a median of $14.1 million recorded in 2021.
  • Peak YoY movement for Cash from Financing Activities: soared 168823.71% in 2021, then tumbled 99.93% in 2022.
  • A 5-year view of Cash from Financing Activities shows it stood at $163.9 million in 2021, then crashed by 99.93% to $115000.0 in 2022, then surged by 34870.43% to $40.2 million in 2023, then soared by 1283.12% to $556.2 million in 2024, then plummeted by 95.32% to $26.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $26.0 million in Q4 2025, $3.1 million in Q3 2025, and $7.1 million in Q2 2025.